Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio
Akebia Therapeutics Inc. has acquired global rights to AKB-097 from Q32 Bio through an Asset Purchase Agreement. Akebia paid $7 million upfront and will pay an additional $3 million after six months. The agreement includes potential milestone payments and tiered royalties on AKB-097 sales. This news was generated by Public Technologies using AI and is based on Akebia's original content published via GlobeNewswire.
Akebia Therapeutics Inc. announced the signing of an Asset Purchase Agreement with Q32 Bio, under which Akebia acquired global rights to Q32 Bio’s ADX-097, now referred to as AKB-097. As part of the agreement, Akebia made an upfront payment of $7.0 million to Q32 Bio and will make an additional $3.0 million payment six months after the closing. The agreement also includes provisions for potential additional development, regulatory, and commercial milestone payments, as well as tiered royalties on annual net sales of AKB-097. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594190-en) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
